Human PAI-2
Inventors:
Stephens; Ross W. (Oslo, NO); Golder; Jeffrey P. (Mona Vale, AU); Antalis;
Toni M. (Toowong, AU); Barnes; Thomas M. (Boston, MA); Clark; Michell A.
(Crows Nest, AU); Devine; Peter L. (Helensvale, AU); Goss; Neil H.
(Wahroonga, AU); Lehrbach; Philip R. (Wahroonga, AU).
Assignee:
Biotechnology Australia, Pty., Ltd. (New South Wales, AU); Australian
National University (Acton, AU).
Appl. No.:
911,531
Filed:
Jul. 15, 1992
Related U.S. Application Data
Continuation-in-part of Ser No. 765,495, Sept. 26, 1991, abandoned and Ser No. 693,542,
Apr. 30, 1991, abandoned, which is a division of Ser. No 25,815, Mar. 13, 1987,
abandoned, said Ser. No. 765,495is a continuation of Ser. No 860,336, Jun. 13, 1986,
abandoned.
Foreign Application Priority Data
Aug. 13, 1984 [AU]
PG6531
Mar. 13, 1986 [AU]
PH5017
May 22, 1986 [AU]
PH6033
Sept. 18, 1986 [AU]
PH8100
Nov. 21, 1986 [AU]
PH9104
Intl. Cl.:
C07K 13/00
U.S. Cl.:
424/ 1.69; 530/350; 530/380; 530/381; 514/ 12
Current U.S. Class:
424/1.69
Field of Search:
530/350, 380, 381; 424/85.91, 1.1, 1.69;
514/12
References Cited [Referenced By:]
U.S. Patent Documents
4,632,981
Dec., 1986
Bock
530/393
4,711,848
Dec., 1987
Insley et al.
435/ 91
4,849,349
Jul., 1989
Ragg et al.
435/ 68.1
4,923,807
May, 1990
Webb et al.
435/ 69.1
4,952,512
Aug., 1990
Loskutoff
435/320.1
5,028,534
Jul., 1991
Sadler et al.
435/ 69.1
Foreign Patent Documents
86/01212
Feb., 1986
WO
Other References
Aoki et al., "Inhibition of Plasminogen Activators by Naturally Occurring Inhibitors in Man",
American Journal on Physiology, 1334-1447 (Dec. 1974).
Astedt et al., "Different Inhibition of One and Two Chain Tissue Plasminogen Activator by a
Placental Inhibitor . . . ", Scand. J. Clin. Lab. Invest. 45: 429-435 (1985).
Astedt et al., "Purification of a Specific Placental Plasminogen Activator Inhibitor by
Monoclonal Antibody and its Complex Formation with Plasminogen Activator", Thrombosis
& Haemostasis, 122-125 (1985).
Auron et al., "Nucleotide Sequence of Human Monocyte Interleukin 1 Precursor cDNA",
Proc. Natl. Acad. Sci., 81:7907-7911 (1984).
Chapman et al., "Macrophage Fibrinolytic Activity: Identification of Two Pathways of Plasmin
Formation by Intact Cells and of a Plasminogen Activagor Inhibitor", Cell, vol. 28: 653-662
(1982).
Chapman et al., "Characterization of a Macrophage-derived Plasminogen-activator Inhibitor",
Biochem. J., 230:109-116 (1985).
Golder et al., "Minactivin: A Human Monocyte Product Which Specifically Inactivates
Urokinase-type Plasminogen Activators", Eur. J. Biochem., 136:518-522 (1983).
Holmberg et al., "Purification of Urokinase by Affinity Chromatography", Biochem. of
Biophysica Acta, 445:215-222 (1976).
Holmberg et al., "An Inhibitor from Placenta Specifically Binds Urokinase and Inhibits
Plasminogen Activator Released from Ovarian Carcinoma . . . ", Biochimica et Biophysica
Acta, 514:128-137 (1978).
Kruithof et al., "Partial Primary Structure of a PA Inhibitor Homologies with Other Serine
Protease Inhibitors", 10th Int'l. Congress on Fibrinetysis, Vienna 1986.
Kruithof et al., "Purification and Characterization of a Fast-acting Inhibotor of Urokinase
(UK) from the Histiocytic Lymphoma Cell-line U-937", 10th Int'l. Congress on Thrombosis
& Haemotosis (1985).
Kruithof et al., "Partial Purification and Characterization of Plasminogen Activator Inhibitor
(PAI-1) mRNA", 10th Int'l. Congress of Thrombosis & Haemotosis, 1985.
Kruithof et al., "Studies on Prourokinase and Plasminogen Activator Inhibitor Biosynthesis in
Phorbol Ester Induced U-937", 10th Int'l. Congress of Thrombosis & Haemotosis, 1985.
Kruithof et al., "Purification and Characterization of a Plasminogen Activator Inhibitor from
the Histiocytic Lymphoma Cell Line U-937", J. Biological Chem., 261(24):11207-11213
(1986).
Kopitar et al., "Human Leucocyte Urokinase Inhibitor--Purification Characterization and
Comparative Studies Against Different Plasminogen Activators", Thrombosis & Haemostasis,
54(4):750-755 (1985).
Lecander et al., "Differential Inhibition of Two Molecular Forms of Melanoma Cell
Plasminogen Activator by a Placental Inhibitor", British J. Haematology, 57:407-412 (1984).
Lecander et al., "Isolation of a New Specific Plasminogen Activator Inhibitor from Pregnancy
Plasma", British J. Haematology, 62:221-228 (1986).
Philips et al., "Immunological Relationship Between the Fast-Acting Plasminogen Activator
Inhibitors from Plasma, Blood Platelets and Endothelial Cells . . . ", Thrombosis &
Haemostasis, 55(2):213-217.
Sakasela et al., "Urokinase-Type Plasminogen Activator and Its Inhibitor Secreted by
Cultured Human Monocyte-Macrophages", J. Cellular Physiology, 132:122-125 (1985).
Van Mourik et al., "Purification of an Inhibitor of Plasminogen Activator (Antiactivator)
Synthesized by Endothelial Cells", J. Biol. Chem., 259(23):14914-14921 (1984).
Vassalli et al., "Human Monocytes-Macrophages and U-937 Cells Synthesize and Secrete a
Plasminogen Activator-Specific Protease Inhibitor", Abstract, 7th International Congress on
Fibrinolysis, Venice, Italy, Mar. 27-30, 1984, Hemostasis, 14(1):95.
Vassalli et al., "Concomitant Secretion of Prourokinase and of a Plasminogen
Activator-Specific Inhibitor by Cultured Human Monocytes-Macrophages", J. Exp. Med.,
1653-1668 (1984).
Webb et al., "Sequence, Chromosomal Assignment, and Homology to Plasminogen
Activator-Inhibitor", J. Exp. Med., 166:77-91 (1987).
Wohlwend et al., "Plasminogen Activator-Specific Inhibitors Produced by Human
Monocytes/Macrophages", J. Exp. Med., 165:320-339 (1987).
Wun et al., "An Inhibitor of Plasminogen Activation from Human Placenta", J. Biol. Chem.,
262(8):3546-3653 (1987).
Ye et al., "cDNA Cloning and Expression in Escherichia coli of a Plasminogen Activator
Inhibitor from Human Placenta", J. Biol. Chem., 262(8):3718-3725 (1987).
Young et al., "Efficient Isolation of Genes by Using Antibody Probes", Proc. Natl. Acad. Sci.,
80:1194-1198 (1983).
Primary Examiner: Schwartz; Richard A.
Assistant Examiner: Brown; Gary L.
Attorney, Agent or Firm: Foley & Lardner
Abstract
Minactivin (also known as Plasminogen Activator Inhibitor-2 [PAI-2]), a protein inactivator of
urokinase-type plasminogen activator, has been shown to be a natural inactivator of this plasminogen
activator which is associated with invasive tumors, and is therefore indicated as a crucial element in
the body's normal defense against tumor invasion and metastasis. It may be produced by the
cultivation of minactivin-producing cells in vitro, and recovery of the cell culture supernatant. By
controlling the culture conditions, the protein minactivin may be produced in a partially purified form
which may be used for diagnosis and treatment of tumors. The specification discloses purification of
biologically active native minactivin, as well as peptides derived from minactivin and their amino acid
sequences. The specification also discloses methods for production of PAI-2 by recombinant DNA
technology, characterization of a PAI-2 gene sequence, and expression and purification of large
quantities of biologically active PAI-2 from a recombinant host.
20 Claims, 72 Drawing Figures |
